IndustryCompany release

DataMEDS AI Q3 revenue up 50% to $2.7M on GLP-1 dispensing

🇺🇸 DataMeds AI, Inc. (MEDS) · Fri 13 Nov 2026

The Nasdaq-listed company says Corexa Pharmacy's GLP-1 dispensing drove growth, and it has regained Nasdaq compliance and launched compounded peptides under an FDA enforcement discretion policy.

DataMEDS AI (NASDAQ: MEDS) reported third-quarter 2026 revenue of $2.7M, up from $1.8M in the second quarter, a rise of 50%. The company attributes the increase to dispensing of GLP-1 drugs through Corexa Pharmacy.

It also posted a net profit of $10.5M for the quarter. The company says this was largely due to extinguished debt and litigation liabilities, not to operating performance, so the figure should be read separately from the revenue trend.

On the regulatory side, the company said it had launched compounded peptides under the FDA's Enforcement Discretion Policy of 30 October 2026. It also said it regained compliance with Nasdaq listing requirements on 19 October. The summary available to us gives no detail on the policy's scope or on which peptides are involved.

Other announcements included a new mobile app, a licence for a REBOOT GLP-1 platform, a non-binding memorandum of understanding with an HMO, and the acquisition of Helomics. No financial terms or timelines for these were provided in the material we reviewed.

What it means for your team

  • Enforcement discretion is not FDA approval. Compounded products are generally not reviewed by the agency for safety or efficacy before they are marketed, so quality and pharmacovigilance oversight remains important.
  • Teams tracking GLP-1 supply should note continued growth in pharmacy-channel dispensing, including through telehealth-linked and compounding-adjacent models.
  • The HMO agreement is a non-binding MOU, so it should not be treated as confirmed market access or a coverage decision.

Company's press release (SEC filing): DataMeds AI, Inc. ↗

Article written by VigiEye from the official source (DataMeds AI, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Industry All →